Publication | Closed Access

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

First-line TherapyMedicineRandomised Phase 3Versus IcotinibPathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology